ClinicaliQ Trial Snapshot
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT07717411.
- Treatment being tested: Trontinemab, a monoclonal antibody targeting Alzheimer's disease pathology, is being evaluated in cognitively unimpaired individuals with biomarker evidence of AD pathology to assess efficacy in slowing or preventing progression to mild cognitive impairment.
- Patient eligibility overview: The trial enrolls asymptomatic individuals who have objective biomarker evidence of AD pathology (amyloid and/or tau) but demonstrate normal cognition and function, representing the earliest detectable stage of Alzheimer's disease pathology.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Eligibility Snapshot
- : * Body weight of 150 kg or less * Willingness and ability to complete all aspects of the study for the duration of the study * Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted) * Cognitively and functionally unimpaired as defined by the protocol * Availability of a study partner as defined by the protocol * A plasma pTau217 level consistent with a high likelihood of future clinical progression
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.